Y-mAbs reports complete GD2-SADA Phase 1 Part A data; safe and well-tolerated

Y-mAbs Therapeutics, Inc.

Part A of Trial 1001 met primary safety objective; no DLTs or treatment-related SAEs across 22 patients.
GD2-SADA PK was dose-dependent, predictable, and reproducible; clearance interval can optimize therapeutic index.
Expanded evaluation showed tumor uptake in 16 of 22 patients across sarcoma, melanoma, and SCLC.
Milestones: CD38-SADA FPI 1H 2025, GD2-Diagnostic IND 2H 2025, new mCRC IND 1H 2027.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.